Our independent approach has set us far ahead of other emerging research efforts in diabetes.
We’ve balanced the backing of prominent institutions with our own unwavering focus on the end goal: the simplest, most accessible treatment that can give people independence from insulin. And we’ve been able to tailor our approach to an already-substantiated regulatory path.
NEWS
PIPELINES
Progress in dogs
ENDSULIN has begun a pilot study in naturally diabetic companion dogs. We are the only group in the world testing gene therapy in large mammals for diabetes with an autoimmune disease.
Dogs are the Ideal preclinical model, because they are the largest animal model with autoimmune diabetes, and the etiology is nearly identical to human type 1 diabetes.
Running the trials in naturally diabetic family dogs rather than only lab-induced canines also allows us to observe the treatment’s effects in a much more realistic situation.
Engineering
Optimization
Pre-clinical
Pilot
Pivotal
Progress in humans
Because of the similarities in dog and human diabetes, successful results in pets should be a strong indicator of how to optimize the human treatment.
Target ID
Pre-clinical
IND-enabling
Clinical trials
This video shows two treated rats, an experimental control and an untreated rat (the smallest animal).
INCREDIBLE IMPACT
Not only could this treatment realistically reach millions of patients with Type 1 diabetes — early signs show it could potentially treat Type 2 diabetes, too.
2-4 insulin injections
every day, on average, to manage the disease. ►Fewer than 2k patients
receive pancreas transplants each year, worldwide. ►Leading cause
of kidney failure, blindness, and vascular disease. ►Even with diligent daily management, many patients still experience severe complications.